Capricor Therapeutics Announces Type-B Meeting With FDA For CAP-1002 Program For Duchenne Muscular Dystrophy, FDA Feedback Supports Requests For Pre-BLA Meeting And Subsequent Rolling BLA Submission Following Upcoming Q2 Type-B FDA Meeting
Capricor Therapeutics Announces Type-B Meeting With FDA For CAP-1002 Program For Duchenne Muscular Dystrophy, FDA Feedback Supports Requests For Pre-BLA Meeting And Subsequent Rolling BLA Submission Following Upcoming Q2 Type-B FDA Meeting
Capricor Therapeutics 宣布与 FDA 就杜兴氏肌肉萎缩症 CAP-1002 计划举行B型会议，美国食品药品管理局的反馈支持BLA前会议的请求以及在即将举行的第二季度Type-B FDA会议之后随后的滚动BLA提交
Capricor Therapeutics Announces Type-B Meeting With FDA For CAP-1002 Program For Duchenne Muscular Dystrophy, FDA Feedback Supports Requests For Pre-BLA Meeting And Subsequent Rolling BLA Submission Following Upcoming Q2 Type-B FDA Meeting
Capricor Therapeutics 宣布与 FDA 就杜兴氏肌肉萎缩症 CAP-1002 计划举行B型会议，美国食品药品管理局的反馈支持BLA前会议的请求以及在即将举行的第二季度Type-B FDA会议之后随后的滚动BLA提交
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。